B7-H3 As a Promising Target for Cytotoxicity T Cell in Human Cancer Therapy

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Apr 29

PMID 27121051

Citations 34

Authors

Juan Ma

Pan Ma

Chenghai Zhao

Xin Xue

Huamin Han

Changzhen Liu

Hua Tao

Weigang Xiu

Jia Cai

Man Zhang

Affiliations

Soon will be listed here.

Abstract

Targeting B7-H3 over-expressed tumor cells with anti-B7-H3 monoclonal antibodies inhibits tumor growth. Here we demonstrated the expression of B7 family homologue 3 (B7-H3) in a wide range of human tumor cells and further investigated whether B7-H3 could be served as a target for T-cell mediated immunotherapy against human cancers. The specific cytotoxic activity of activated T cell (ATC) armed with a novel anti-CD3 x anti-B7-H3 bispecific antibody (B7-H3Bi-Ab) against tumor cell was evaluated in vitro and in vivo. In contrast with unarmed ATC, an increase in cytotoxic activity of B7-H3Bi-armed ATC against tumor cells was observed at effector/target (E/T) ratios of 5:1, 10:1, and 20:1. Moreover, B7-H3Bi-armed ATC secreted more IFN-γ, TNF-α and IL-2 than unarmed ATC. Infusion of B7-H3Bi-armed ATC inhibited tumor growth in severe combined immunodeficiency (SCID) xenograft models, along with a significant survival benefit. Therefore, treatment with novel B7-H3Bi-armed ATC will be a promising strategy for current cancer immunotherapy.

Citing Articles

Genetic Risk Profiling Reveals Altered Glycosyltransferase Expression as a Predictor for Patient Outcome in Neuroblastoma.

Bley I, Behrens S, Spohn M, Muller I, Schattling B J Clin Med. 2025; 14(2.

PMID: 39860532 PMC: 11766279. DOI: 10.3390/jcm14020527.

Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer.

Shen Q, Zhou K, Lu H, Zhang J, Xu Q, Zhang C Discov Oncol. 2024; 15(1):822.

PMID: 39709589 PMC: 11663829. DOI: 10.1007/s12672-024-01674-x.

B7-H3 in glioblastoma and beyond: significance and therapeutic strategies.

Babic D, Jovcevska I, Zottel A Front Immunol. 2024; 15():1495283.

PMID: 39664380 PMC: 11632391. DOI: 10.3389/fimmu.2024.1495283.

Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy.

Du G, Dou C, Sun P, Wang S, Liu J, Ma L Front Immunol. 2024; 15:1431211.

PMID: 39136031 PMC: 11317284. DOI: 10.3389/fimmu.2024.1431211.

Survival and clinicopathological significance of B7-H3 in bladder cancer: a systematic review and meta-analysis.

Sun H, Gao F, Liu Y, Shao J BMC Urol. 2024; 24(1):57.

PMID: 38468228 PMC: 10929094. DOI: 10.1186/s12894-024-01446-3.

References

Lum L, Thakur A . Targeting T cells with bispecific antibodies for cancer therapy. BioDrugs. 2011; 25(6):365-79. PMC: 3792709. DOI: 10.2165/11595950-000000000-00000. View

Lum L, Davol P, Lee R . The new face of bispecific antibodies: targeting cancer and much more. Exp Hematol. 2006; 34(1):1-6. DOI: 10.1016/j.exphem.2005.07.013. View

Sun T, Gao Q, Qiu S, Zhou J, Wang X, Yi Y . B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence. Cancer Immunol Immunother. 2012; 61(11):2171-82. PMC: 11029627. DOI: 10.1007/s00262-012-1278-5. View

Mao Y, Li W, Chen K, Xie Y, Liu Q, Yao M . B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget. 2015; 6(5):3452-61. PMC: 4413666. DOI: 10.18632/oncotarget.3097. View

Yankelevich M, Kondadasula S, Thakur A, Buck S, Cheung N, Lum L . Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. Pediatr Blood Cancer. 2012; 59(7):1198-205. PMC: 3792711. DOI: 10.1002/pbc.24237. View

Fu X, Tao L, Rivera A, Williamson S, Song X, Ahmed N . A simple and sensitive method for measuring tumor-specific T cell cytotoxicity. PLoS One. 2010; 5(7):e11867. PMC: 2912327. DOI: 10.1371/journal.pone.0011867. View

Zhao X, Zhang G, Gan W, Xiong F, Li Z, Zhao H . Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma. Oncol Lett. 2013; 5(3):805-812. PMC: 3576185. DOI: 10.3892/ol.2013.1118. View

Renner C, Held G, Ohnesorge S, Bauer S, Gerlach K, Pfitzenmeier J . Role of perforin, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody-activated cytotoxic T cells. Cancer Immunol Immunother. 1997; 44(2):70-6. PMC: 11037813. DOI: 10.1007/s002620050357. View

Clay T, Custer M, SACHS J, Hwu P, Rosenberg S, Nishimura M . Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol. 1999; 163(1):507-13. View

10.

Seliger B, Quandt D . The expression, function, and clinical relevance of B7 family members in cancer. Cancer Immunol Immunother. 2012; 61(8):1327-41. PMC: 11028783. DOI: 10.1007/s00262-012-1293-6. View

11.

Baral A, Ye H, Jiang P, Yao Y, Mao Y . B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients. Oncol Lett. 2014; 8(3):1195-1201. PMC: 4114642. DOI: 10.3892/ol.2014.2268. View

12.

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

13.

Yamato I, Sho M, Nomi T, Akahori T, Shimada K, Hotta K . Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer. 2009; 101(10):1709-16. PMC: 2778545. DOI: 10.1038/sj.bjc.6605375. View

14.

Kang F, Wang L, Jia H, Li D, Li H, Zhang Y . B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway. Cancer Cell Int. 2015; 15:45. PMC: 4407415. DOI: 10.1186/s12935-015-0195-z. View

15.

Fousek K, Ahmed N . The Evolution of T-cell Therapies for Solid Malignancies. Clin Cancer Res. 2015; 21(15):3384-92. PMC: 4526112. DOI: 10.1158/1078-0432.CCR-14-2675. View

16.

Zhang G, Xu Y, Lu X, Huang H, Zhou Y, Lu B . Diagnosis value of serum B7-H3 expression in non-small cell lung cancer. Lung Cancer. 2009; 66(2):245-9. DOI: 10.1016/j.lungcan.2009.01.017. View

17.

Masuda A, Arai K, Nishihara D, Mizuno T, Yuki H, Kambara T . Clinical significance of serum soluble T cell regulatory molecules in clear cell renal cell carcinoma. Biomed Res Int. 2014; 2014:396064. PMC: 4095742. DOI: 10.1155/2014/396064. View

18.

Loos M, Hedderich D, Friess H, Kleeff J . B7-h3 and its role in antitumor immunity. Clin Dev Immunol. 2010; 2010:683875. PMC: 2993024. DOI: 10.1155/2010/683875. View

19.

Ma J, Han H, Liu D, Li W, Feng H, Xue X . HER2 as a promising target for cytotoxicity T cells in human melanoma therapy. PLoS One. 2013; 8(8):e73261. PMC: 3754977. DOI: 10.1371/journal.pone.0073261. View

20.

Loo D, Alderson R, Chen F, Huang L, Zhang W, Gorlatov S . Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res. 2012; 18(14):3834-45. DOI: 10.1158/1078-0432.CCR-12-0715. View